This month we meet with MHRA, Professor David Taylor and Professor James MacCabe.  MHRA are currently conducting a full review on clozapine use.  We need to take this opportunity and ensure their review focuses on the much needed improvements below.   

If you have a moment and could email MHRA to request the following changes it would be most appreciated.  Email Address: MHRACustomerServices@mhra.gov.uk

1. Licensing laws need changing regarding restarting clozapine and off license agreements. Patients should be allowed to start back on clozapine once a green result is obtained.
2. Reduce the frequency of blood monitoring to every 3 months after 12-18 months use. TDM to become mandatory every 3 months at the same time as blood monitoring, which would increase the monitoring and safety for clozapine toxicity.
3. Threshold for RED result to be lowered in line with USA and cease platelet and white cell counts.
4. Revision of the current guidelines and views for ‘therapeutic levels’ and ‘target maintenance doses’
5. Fingerstick testing (MyCare/ Athelas device) made available to every clozapine user, which would also give immediate TDM serum level results.
6. Allow readily available access to supplies of clozapine to avoid unnecessary stoppages